Home
/ AbbVie
/ Financials & Metrics

AbbVie (ABBV) stock price, revenue, and financials

AbbVie market cap is $188.6 b, and annual revenue was $33.27 b in FY 2019

View Company

-1.19 (-1.11%)

$188.6 B

ABBV Mkt cap, 08-Feb-2021

$12.9 B

AbbVie Revenue Q3, 2020

AbbVie Gross profit (Q3, 2020)7.9 B

AbbVie Gross profit margin (Q3, 2020), %60.9%

AbbVie Net income (Q3, 2020)2.3 B

AbbVie EBIT (Q3, 2020)3.3 B

AbbVie Cash, 30-Sept-20207.9 B

AbbVie EV267.8 B

AbbVie Revenue

AbbVie revenue was $33.27 b in FY, 2019 which is a 1.6% year over year increase from the previous period.

Embed Graph

AbbVie Revenue Breakdown

Geographic Segment

Embed Graph

AbbVie revenue breakdown by geographic segment: 28.1% from International and 71.9% from United States

Annual

USD	FY, 2016	FY, 2017	FY, 2018	FY, 2019
Revenue	25.6b	28.2b	32.8b	33.3b
Revenue growth, %	12%	10%	16%	2%
Cost of goods sold	5.8b	7.0b	7.7b	7.4b
Gross profit	19.8b	21.2b	25.0b	25.8b
Gross profit Margin, %	77%	75%	76%	78%
R&D expense	4.4b	5.0b	10.3b	6.4b
General and administrative expense	5.9b	6.3b	7.4b	6.9b
Operating expense total	10.4b	11.6b	18.7b	13.3b
EBIT	9.4b	9.6b	6.4b	13.0b
EBIT margin, %	37%	34%	19%	39%
Interest expense	965.0m	1.0b	1.1b	1.5b
Pre tax profit	7.9b	7.7b	5.2b	8.4b
Income tax expense	1.9b	2.4b	(490.0m)	544.0m
Net Income	6.0b	5.3b	5.7b	7.9b
EPS	3.6	3.3	3.7	5.3

Quarterly

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Revenue	6.5b	6.9b	7.0b	7.9b	8.3b	8.2b	7.8b	8.3b	8.5b	8.6b	10.4b	12.9b
Cost of goods sold	1.6b	1.5b	1.6b	1.9b	1.9b	1.8b	1.7b	1.8b	1.9b	1.9b	3.7b	5.1b
Gross profit	4.9b	5.4b	5.4b	6.0b	6.3b	6.4b	6.1b	6.4b	6.6b	6.7b	6.7b	7.9b
Gross profit Margin, %	75%	78%	77%	76%	77%	78%	78%	78%	77%	77%	64%	61%
R&D expense	1.1b	1.2b	1.2b	1.2b	1.3b	1.3b	1.3b	1.3b	2.3b	1.4b	1.6b	1.7b
General and administrative expense	1.4b	1.5b	1.5b	1.8b	1.8b	1.9b	1.7b	1.7b	1.7b	1.7b	3.5b	2.8b
Operating expense total	2.5b	2.7b	2.7b	3.1b	3.6b	3.2b	3.1b	3.0b	3.9b	3.1b	6.0b	4.6b
EBIT	2.4b	2.7b	2.7b	2.9b	2.8b	3.2b	3.0b	3.4b	2.6b	3.6b	752.0m	3.3b
EBIT margin, %	37%	39%	39%	37%	33%	38%	38%	41%	31%	42%	7%	25%
Interest expense	247.0m	253.0m	252.0m	251.0m	272.0m	302.0m	325.0m	309.0m	420.0m	428.0m	614.0m	620.0m
Pre tax profit	2.1b	2.4b	2.1b	2.8b	2.0b	2.8b	2.5b	807.0m	2.0b	3.1b	(693.0m)	2.5b
Income tax expense	375.0m	438.0m	464.0m	14.0m	29.0m	14.0m	88.0m	66.0m	117.0m	88.0m	46.0m	187.0m
Net Income	1.7b	1.9b	1.6b	2.8b	2.0b	2.7b	2.5b	741.0m	1.9b	3.0b	(739.0m)	2.3b
EPS	1.1	1.2	1.0	1.7	1.3	1.8	1.7	0.5	1.3	2.0	(0.5)	1.3

Annual

USD	FY, 2016	FY, 2017	FY, 2018	FY, 2019
Cash	5.1b	9.3b	7.3b	39.9b
Accounts Receivable	4.8b	5.1b	5.4b	5.4b
Prepaid Expenses	3.6b	4.7b	1.9b	2.4b
Inventories	1.4b	1.6b	1.6b	1.8b
Current Assets	16.2b	21.2b	16.9b	49.5b
PP&E	2.6b	2.8b	2.9b	3.0b
Goodwill	15.4b	15.8b	15.7b	15.6b
Total Assets	66.1b	70.8b	59.4b	89.1b
Accounts Payable	9.4b	10.2b	1.5b	11.8b
Short-term debt	402.0m	6.4b	5.3b	3.8b
Current Liabilities	9.8b	16.6b	17.2b	15.6b
Long-term debt	36.4b	31.0b	35.0b	63.0b
Total Debt	36.8b	37.4b	40.3b	66.7b
Common Stock	18.0m	18.0m	18.0m	18.0m
Additional Paid-in Capital	13.7b	14.3b	14.8b	15.2b
Retained Earnings	4.4b	5.5b	3.4b	4.7b
Total Equity	4.6b	5.1b	(8.4b)	(8.2b)
Debt to Equity Ratio	7.9 x	7.3 x	-4.8 x	-8.2 x
Debt to Assets Ratio	0.6 x	0.5 x	0.7 x	0.7 x
Financial Leverage	14.3 x	13.9 x	-7 x	-10.9 x

Quarterly

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Cash	4.7b	6.1b	8.4b	9.0b	3.5b	8.0b	4.9b	5.2b	10.6b	41.1b	6.0b	7.9b
Accounts Receivable	4.7b	4.9b	4.9b	5.8b	5.8b	5.8b	5.7b	5.5b	5.5b	6.4b	8.4b	8.4b
Prepaid Expenses	3.2b	3.3b	2.7b	3.4b	2.7b	2.1b	1.8b	2.3b	2.1b	2.4b	2.8b	3.2b
Inventories	1.4b	1.6b	1.8b	1.7b	1.6b	1.8b	1.7b	1.9b	1.9b	1.8b	4.1b	3.5b
Current Assets	15.5b	17.0b	18.9b	20.4b	13.8b	18.5b	14.4b	15.1b	20.2b	51.8b	21.3b	23.0b
PP&E	2.6b	2.7b	2.7b	2.8b	2.8b	3.0b	2.9b	2.9b	2.9b	3.0b	4.9b	5.0b
Goodwill	15.5b	15.7b	15.7b	15.9b	15.7b	15.7b	15.6b	15.6b	15.5b	15.6b	42.7b	42.8b
Total Assets	65.7b	67.0b	68.8b	69.3b	61.6b	66.2b	56.8b	57.1b	59.4b	91.2b	149.5b	149.6b
Accounts Payable	8.4b	8.8b	9.2b	10.7b	10.7b	11.4b	11.8b	11.3b	12.2b	12.7b	19.3b	19.4b
Short-term debt	425.0m	3.4b	3.8b	6.4b	6.5b	4.0b	2.1b	5.6b	5.3b	3.8b	5.4b	4.8b
Current Liabilities	8.8b	12.3b	13.0b	17.1b	17.2b	15.4b	13.9b	16.9b	17.5b	16.5b	24.6b	24.2b
Long-term debt	36.5b	33.8b	34.0b	30.9b	30.6b	36.5b	35.1b	31.6b	33.1b	63.3b	82.1b	82.3b
Total Debt	37.0b	37.2b	37.8b	37.3b	37.1b	40.5b	37.1b	37.3b	38.4b	67.0b	87.4b	87.1b
Common Stock	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m	18.0m
Additional Paid-in Capital	13.9b	14.0b	14.2b	14.5b	14.6b	14.7b	14.9b	15.0b	15.1b	15.4b	17.0b	17.1b
Retained Earnings	5.1b	6.0b	6.5b	5.0b	5.5b	6.8b	4.2b	3.4b	3.7b	6.0b	3.1b	3.3b
Total Equity	5.0b	6.0b	6.7b	3.6b	(3.4b)	(2.9b)	(7.8b)	(8.6b)	(8.2b)	(7.4b)	14.7b	15.3b
Debt to Equity Ratio	7.4 x	6.2 x	5.7 x	10.5 x	-11 x	-13.9 x	-4.7 x	-4.3 x	-4.7 x	-9 x	5.9 x	5.7 x
Debt to Assets Ratio	0.6 x	0.6 x	0.5 x	0.5 x	0.6 x	0.6 x	0.7 x	0.7 x	0.6 x	0.7 x	0.6 x	0.6 x
Financial Leverage	13.1 x	11.1 x	10.3 x	19.5 x	-18.3 x	-22.7 x	-7.3 x	-6.7 x	-7.2 x	-12.3 x	10.2 x	9.8 x

Annual

USD	FY, 2016	FY, 2017	FY, 2018	FY, 2019
Net Income	6.0b	5.3b	5.7b	7.9b
Depreciation and Amortization	1.2b	1.5b	1.8b	2.0b
Accounts Receivable	(71.0m)	(391.0m)	(591.0m)	(74.0m)
Inventories	(38.0m)	93.0m	(226.0m)	(231.0m)
Accounts Payable	(1.2b)	425.0m	190.0m	(1.1b)
Cash From Operating Activities	7.0b	10.0b	13.4b	13.3b
Purchases of PP&E	(479.0m)	(529.0m)	(638.0m)	(552.0m)
Cash From Investing Activities	(6.1b)	(274.0m)	(1.0b)	596.0m
Short-term Borrowings	(29.0m)	22.0m	299.0m	(3.7b)
Long-term Borrowings	(6.0b)	(25.0m)	(6.0b)	(1.5b)
Dividends Paid	(3.7b)	(4.1b)	(5.6b)	(6.4b)
Cash From Financing Activities	(3.9b)	(5.5b)	(14.4b)	18.7b
Net Change in Cash	(3.3b)	4.2b	(2.0b)	32.6b
Interest Paid	986.0m	1.1b	1.2b	1.8b
Income Taxes Paid	3.6b	1.7b		1.4b

Quarterly

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Net Income	1.7b	3.6b	5.3b	2.8b	4.8b	7.5b	2.5b	3.2b	5.1b	3.0b	2.3b	4.6b
Depreciation and Amortization	374.0m	753.0m	1.1b	445.0m	888.0m	1.3b	503.0m	1.0b	1.5b	559.0m	264.0m	4.4b
Accounts Receivable	(34.0m)	(167.0m)	(163.0m)	(681.0m)	(805.0m)	(806.0m)	(316.0m)	(96.0m)	(207.0m)	(1.0b)	(543.0m)	(574.0m)
Inventories	71.0m	1.0m	(119.0m)	(71.0m)	(191.0m)	(367.0m)	(128.0m)	(288.0m)	(401.0m)	(107.0m)	(304.0m)	(193.0m)
Accounts Payable	(266.0m)	(530.0m)	444.0m	191.0m	12.0m	881.0m	94.0m	(1.3b)	(582.0m)	1.1b	466.0m	1.9b
Cash From Operating Activities	2.1b	4.1b	7.4b	2.6b	5.5b	10.0b	3.0b	5.5b	10.0b	3.8b	6.9b	12.7b
Purchases of PP&E	(95.0m)	(221.0m)	(347.0m)	(119.0m)	(233.0m)	(515.0m)	(107.0m)	(235.0m)	(389.0m)	(125.0m)	(302.0m)	(519.0m)
Cash From Investing Activities	(684.0m)	(366.0m)	(475.0m)	(447.0m)	240.0m	(723.0m)	(27.0m)	(167.0m)	1.2b	(129.0m)	(35.8b)	(36.9b)
Short-term Borrowings	23.0m	23.0m	423.0m	(33.0m)	111.0m	(400.0m)	(200.0m)	(393.0m)	(699.0m)
Long-term Borrowings	(6.0m)	(13.0m)	(18.0m)	(7.0m)	(3.0b)	(5.0b)	(3.0b)	(3.0b)	(3.0b)		(3.8b)	(4.4b)
Dividends Paid	(1.0b)	(2.1b)	(3.1b)	(1.1b)	(2.7b)	(4.1b)	(1.6b)	(3.2b)	(4.8b)	(1.8b)	(3.5b)	(5.6b)
Cash From Financing Activities	(1.8b)	(2.8b)	(3.6b)	(2.5b)	(11.5b)	(10.6b)	(5.4b)	(7.5b)	(7.9b)	(2.4b)	(5.0b)	(7.8b)
Net Change in Cash	(360.0m)	988.0m	3.3b	(296.0m)	(5.8b)	(1.3b)	(2.4b)	(2.1b)	3.4b	1.2b	(33.9b)	(32.0b)

USD	FY, 2016
Revenue/Employee	915.6k
Debt/Equity	7.9 x
Debt/Assets	0.6 x
Financial Leverage	14.3 x

AbbVie's Patients was reported to be 52 m in FY, 2019.

	FY, 2018	FY, 2019	Mar, 2020
Active Clinical Trials (Oncology)	200
Countries	175	175
Exploratory Phase Products (Calico)			8
Exploratory Phase Products (Immunology)			33
Exploratory Phase Products (Neuroscience)			5
Exploratory Phase Products (Oncology)			45
Exploratory Phase Products (Other)			1
Manufacturing Facilities	14	14
Manufacturing and R&D Facilities	14
Partners	220
Patient Support Programs (US)	90
Patients	30 m	52 m
Patients Included in Clinical Trials	104 k
Patients Included in Clinical Trials (US)	40 k
Patients Treated (Immunology)	1 m
Phase I Trials Products (Immunology)			2
Phase I Trials Products (Neuroscience)			3
Phase I Trials Products (Oncology)			18
Phase I Trials Products (Other)			1
Phase II Trials Products (Immunology)			6
Phase II Trials Products (Neuroscience)			2
Phase II Trials Products (Oncology)			3
Phase II Trials Products (Other)			2
Phase III Trials Products (Immunology)			11
Phase III Trials Products (Neuroscience)			1
Phase III Trials Products (Oncology)			13
Phase III Trials Products (Other)			1
Preclinical Phase Products (Calico)			2
Preclinical Phase Products (Immunology)			3
Preclinical Phase Products (Oncology)			7
Preclinical Phase Products (Other)			4
Programs	292
Research and Development Centers	8	8
Suppliers	51 k

	FY, 2019
Water Withdrawn	31.70 m cubic meters
Water Consumed	4.33 m cubic meters
Waste Generated	33.40 k metric tons
Waste Disposed	9.80 k metric tons
Total Recordable Incident Rate	0.25
Lost Time Incident Rate	0.09
Hazardous Waste Generated	17.70 k metric tons
Greenhouse Gas Emissions (Scope 2, Carbon Dioxide)	250 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 1, Carbon Dioxide)	315 k metric tons of carbon dioxide equivalent
Energy Consumption	2.11 m MWh
Air Emissions (Carbon Dioxide)	564 k metric tons of carbon dioxide equivalent

Job Roles

	FY, 2019	FY, 2018	FY, 2017
Male (Management), percent	24.6 %	25.1 %	25.3 %
Male (Top Managers), percent	31 %	30.9 %	29.6 %
Female (Management), percent	22.7 %	22.3 %	22.3 %
Female (Top Managers), percent	16.4 %	16.5 %	18 %
Other	5.2 %	5.2 %	4.8 %